Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This company is bound for great things
So any EPIX holders or opinions out there? Surprised nothing on here. Solid Ph 1 thus far, full report coming in a couple months. Consensus around $4B peak sales, discounting back from that to today and it's worth a couple hundred bucks. Disclosure: long since 2018, $4.43 avg price and holding strong.
Wake up starting to move again. Up 11.62% today at 15.25
New colaberation with Jansen Research for metastatic prostate cancer.
Revoked on a day when the markets are closed, just seems weird.
EPIX: SEC Suspension:
http://www.sec.gov/litigation/suspensions/2012/34-67933.pdf
ORDER:
http://www.sec.gov/litigation/suspensions/2012/34-67933-o.pdf
Buy at the bid and sell at the ask. Double your money
YEP- count me in!!! glad I stumbled on this one!
good solid day here. huge volume. opened at .005 ran up some but held the open and gains all day. let's see what next week bring for EPIX
well, let's hope for the best. ya never know. LAFC just jumped up to .0055 now so he isn't sharing top bid here. definitely something for all who notice this stock to look at. watch how this trades and the MM behavior. today's volume has come out of nowhere.
also, I dont think LAFC ever buys on the ask, I wouldn't know, but they always sit bid and push for top bid. they are a smart institution when they want to buy what they do. That's why I bought today. that and the volume.
and thanks on that other one. i know you dont have PM's so i appreciate the tip, probably best to keep other tickers off another board. i'm no mod here so its whatever.
If you notice, LAFC is also bidding on TDLPQ, which is another pharm company about to be bought out for .50 a share.Transdel Pharm, the news is getting around.
same here, I'll hold and sit tight. the volume caught my attention, i agree, something is probably up.
not sure legit, I used a scanner months ago and this one popped up because of s/s. It was a lotto play for me because I like pharm companies. Per their website, they decided to settle with creditos instead of a bk. you can google them. But something is definitely up. I know Im keeping my shares just in case.
volume today:
average 5 day vol = 80k
10 day vol = 66k
15 day avg vol = 45k
today volume so far = 2.2mil
something might be up but i can't figure it out. it hasn't dropped under what it opened at either.
NITE boxing it in this range imo. not sure why
if anyone has any info on EPIX please share
LAFC = marketmaker R. F. Lafferty & Co., Inc.
Their Investment Banking services include:
* Mergers and Acquisitions
* Reverse Mergers
* PIPE Transactions
* Private Placements
* Initial Public Offerings
* Bridge Financing
* Assistance with Exchange Listings
good to see him on the bid side smile
Who is LAFC? Im in from .003. TD ameritrade shows 75 mil o/s shares.
looks pretty good so far today. look at the volume. I'm watching it trade, not bad yet.
this may be a long term hold. all of my CVSL folks know about MM LAFC loading at top bid. lafc sitting at .0055 and is on the ask at .03
nite sitting at .007 with a decent sized order (also on the bid with a big order) looks to be boxing it in some.
Support at .005 is clear, thin to .007 thats why that hit.
8/08: Outstanding approx 42M...A/S is unav and float is unav on otc
Down to open. Looks like a pump.
EPIX big volume today. LAFC bidding. whats up here, whats the s/s?
I see share purchased everyday but I cant find a thing..I'm also wondering whats up.
Does this thing have any chance of doing anything....worthwhile ??
Sold earlier in the week for a loss. Might get back in later.
Uh...guess not, huh? What happened to the ATM machine? Pitiful...
Still in this??? "Huge moves" LOL
Gee...no reverse merger and back to .004. What a surprise.
funny> people are buying but noooo one is talking...haha
Somethings up? a 90k buy at the open
I've noticed some volume here> anyone know what's up
Absolutely not...no indication that this will run again anytime soon.
There aren't any true facts because nothing is currently going on with this company. Its that simple.
Are you loading up on EPIX?
Seems like the bottom has been established.
Good call LOL
I haven't bashed this stock at all, only those who were pushing the R/M as a done deal. This may have future potential but nothing is currently in the works. If that is negative (or "negitive" as you spell it) then so be it.
I am all for a little balance. But wouldnt it be better to put a truthful spin on it instead of balancing neg and pos. (not that the truth wouldnt be negitive)
If everything said is negitive then you are bashing not balancing. If everything is truth and positive you dont just throw negitive lies in it just to balance.
I just started looking at this stock and might have been warned off by a truthful post from you but with the need to make a "negitive spin" you discredited yourself and were seen as a basher. Please tell me the true facts good or bad.
Same goes for the pumpers out there.
Are you buying .01's today?
So far so bad. 009x01
Still working it hard I see~
Isn't that the truth. They were handing me $$$$ and I was like, oh, no that's ok, you keep it! What a joke I am sometimes.
I'll take it next time for sure! At least I hope I do!
Good luck to you too.
As far as the SEC document from a private company:
Under Section 12(g) of the Exchange Act, a private company with total assets in excess of $10 million and 500 or more record holders of a class of equity security, each measured at the end of its fiscal year, must register the class of equity security with the Securities and Exchange Commission, unless it has an exemption from such registration. Stock options are considered to be a separate class of equity security under the Exchange Act. Accordingly, a company with 500 or more option holders (including holders of unvested options) and more than $10 million in assets is required to register its stock options under the Exchange Act, absent an exemption.
But, more than likely, they were shares already in the market.
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1332
|
Created
|
08/31/07
|
Type
|
Free
|
Moderators |
EPIX Pharmaceuticals, Inc.,
a biopharmaceutical company, engages in the discovery and development of therapeutics through the use of its proprietary silico drug discovery platform. The company's therapeutic product candidates in development include PRX-08066 that completed Phase IIa clinical trial for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease; PRX-03140, which is in Phase IIa clinical trial for the treatment of Alzheimer's disease; PRX-00023, which is in Phase IIb clinical trial for the treatment of depressive disorder; and PRX-07034, which is in Phase Ib clinical trial for the treatment of obesity and cognitive impairment associated with schizophrenia. Its imaging agents comprise Vasovist, an injectable intravascular contrast agent that provides enhanced imaging of the vascular system using magnetic resonance angiography; and EP-2104R that enables the identification of blood clots using MRI. EPIX Pharmaceuticals has collaborations with SmithKline Beecham Corporation; Amgen, Inc.; Cystic Fibrosis Foundation Therapeutics Incorporated; and Bayer Schering Pharma AG, Germany. The company was founded in 1988 as Metacorp, Inc. and changed its name to METASYN, Inc. in May 1989. It further changed its name to EPIX Medical, Inc. in May 1996 and then to EPIX Pharmaceuticals Inc. in September 2004. EPIX Pharmaceuticals Inc. is headquartered in Lexington, Massachusetts.
Homepage EPIX Pharmaceuticals: http://www.epixpharma.com/ - (781) 761-7600
Yahoo Key Statistics: http://finance.yahoo.com/q/ks?s=EPIX.OB - Enterprise Value August 19, 2009: $86.49M
)
Factsheet Epix December 2007
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=epix
Company Information
Recent News
The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer's Disease. The patient was enrolled initially in a two week Phase 2a study in August 2007 where she received 100 mg per day of PRX-03140 in combination with her normal daily dose of Aricept((R))(10 mg). Based on the marked progress during the original two week study, the patient's daughter sought continued compassionate use of PRX-03140 for her mother and a protocol was submitted to the FDA and approved. The progress seen in the first 2-week study has continued during the past two years (19 months of dosing) and four FDA approved 6-month open label extensions. The latest open label extension will be administered under a new Physician-Sponsored IND under the supervision of Dr. Lucy Hornstein(1). "When I was approached by the patient's daughter to continue the compassionate use therapy of PRX-03140 for her mother, I was compelled by the progress her mother had experienced and the overall apparent safety of the drug," notes Dr. Hornstein.
On July 20, 2009, EPIX Pharmaceuticals, Inc. (the "Company") entered into an Assignment for the Benefit of Creditors (the "Assignment") in accordance with Massachusetts law. The purpose of the Assignment is to conclude the Company's operations and provide for an orderly liquidation of its assets. The Assignment is a common law business liquidation mechanism under Massachusetts law that is an alternative to a formal bankruptcy proceeding. Under the terms of the Assignment, the Company transferred all of its assets to an assignee for orderly liquidation and distribution of the proceeds to the Company's creditors. The designated assignee for the Company is Joseph F. Finn, Jr. at Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481.
The PRX-03140 program will be sold at auction on Wednesday, October 21 at 3 pm EDT. Please contact Joseph F. Finn, Jr. at 781-237-8840 if you are interested in participating in the auction.
SOURCE Joseph F. Finn, Jr., C.P.A.
EPIX PHARMACEUTICALS ANNOUNCES THE P2Y2 GASTROINTESTINAL PROGRAM
Sep 01, 2009 (AsiaPulse via COMTEX) -- MEDIA RELEASE PR35934
(Full text of statement. Contact details below.)
EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
WELLESLEY HILLS, Mass., Sept. 2 /PRNewswire-AsiaNet/ --
Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the intellectual property offered for sale at the September 30, 2009 auction.
The P2Y2, an Early Development Candidate Program, is a small molecule, oral, non-absorbed agonist for treatment of constipation.
The intellectual property, regulatory dossier and clinical inventory will be sold at auction on September 30, 2009.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.
He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net
SOURCE:: Joseph F. Finn, Jr., C.P.A.
Share Structure and Company Information
EPIX Pharmaceuticals, Inc. 4 Maguire Road Lexington, MA 02421
|
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |